Stay updated with breaking news from Laser System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
![Photonics Market Size, Share, Growth [2023-2029] To USD 974.13 Bn, While Exhibiting an Impressive CAGR of 6.26% - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
/PRNewswire/ -- Exactitude Consultancy explores the current market and new opportunities in the growing Photonics Market. Is technological advancement or price...
According to Exactitude Consultancy the Global Photonics Market value is expected to reach USD 974.13 Bn by 2029, growing at a 6.26% CAGR of Between Forecast Period 2023 to 2029 PUNE, India
/PRNewswire/ -- Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies...
Get latest articles and stories on Business at LatestLY. Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical trial (ASP-1929-301/ClinicalTrials.gov Identifier: NCT03769506) evaluating Alluminox treatment (photoimmunotherapy) using ASP-1929 in patients with locoregional, recurrent hea...
Rakuten Medical, a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization CDSCO to conduct its global, pivotal Phase 3 clinical trial ASP-1929-301ClinicalTrials.gov Identifier NCT03769506 evaluating Alluminox treatment photoimmunotherapy using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas HNSCC in India, and the registration of clinical trial infor...